About Nurix Therapeutics
Nurix Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. It uses its DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607 and DeTIL-0255. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Its E3 ligase inhibitor portfolio is comprised of a series of small molecule inhibitors of CBL-B, which functions as an intracellular checkpoint regulating activation of T cells, B-cells and NK cells.